Takeda Highlights Late-Stage Pipeline with Potential Blockbuster Drugs
核心洞察
Takeda (搜索) is advancing six late-stage programs with a potential peak revenue of $10B-$20B, aiming for sustainable growth through innovative therapies.
Phase 3 data readouts are expected in 2025 for oveporexton (TAK-861) in narcolepsy, zasocitinib (TAK-279) in psoriasis (搜索), and rusfertide (TAK-121 (搜索)) in polycythemia vera (搜索).
Regulatory filings for oveporexton, zasocitinib, and rusfertide are on track for fiscal years 2025-2026, with additional filings anticipated through 2029.
Takeda (搜索) Pharmaceutical is focusing on its late-stage pipeline, which includes six programs with the potential to generate $10 billion to $20 billion in peak revenue. These programs are aimed at delivering transformative value to patients across multiple therapeutic areas and driving sustainable growth for the company.
Upcoming Phase 3 Readouts and Regulatory Filings
In 2025, Takeda (搜索) anticipates Phase 3 data readouts for three key programs: oveporexton (TAK-861) for narcolepsy type 1 (搜索), zasocitinib (TAK-279) for psoriasis (搜索), and rusfertide (TAK-121 (搜索)) for polycythemia vera (搜索). Regulatory filings for these indications are expected in fiscal years 2025 and 2026.
Key Programs in Development
- Oveporexton (TAK-861): An investigational oral orexin receptor 2 agonist, potentially best-in-class and first-in-class, for the treatment of narcolepsy type 1.
- Zasocitinib (TAK-279): A next-generation, highly selective, and potent oral allosteric tyrosine kinase 2 (TYK2) inhibitor being developed for psoriasis and psoriatic arthritis.
- Rusfertide (TAK-121): An injectable hepcidin mimetic in development with Protagonist Therapeutics for the treatment of polycythemia vera.
- Mezagitamab (TAK-079): An anti-CD38 antibody providing rapid, selective, and sustained depletion of disease-causing immune cells, potentially setting a new standard for treating immune thrombocytopenia (ITP) and immunoglobulin A nephropathy (IgAN).
- Fazirsiran (TAK-999): An RNA interference (RNAi) therapy that halts the production of misfolded abnormal protein Z-AAT, directly addressing the pathology of alpha-1 antitrypsin deficiency liver disease (AATD-LD).
- Elritercept (TAK-226): An activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes (MDS). Takeda recently signed an exclusive licensing agreement with Keros Therapeutics to further develop, manufacture, and commercialize elritercept worldwide outside of mainland China, Hong Kong, and Macau.
Strategic Focus and R&D Investment
According to Andy Plump, president of R&D at Takeda (搜索), the company is focused on scaling its capabilities and maximizing R&D investment to deliver the late-stage pipeline. Takeda is also progressing an early-stage pipeline and focusing on creative business development across its therapeutic areas to sustain its future and meet significant unmet patient needs.